Carisma Therapeutics (CARM) Tops Q3 EPS by 4c

Carisma Therapeutics (NASDAQ: CARM) reported Q3 EPS of ($0.53), $0.04 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $3.83 million versus the consensus estimate of $1.1 million.

For earnings history and earnings-related data on Carisma Therapeutics (CARM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c